130 related articles for article (PubMed ID: 23058498)
1. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Zhang HL; Zhu Y; Qin XJ; Wang CF; Yao XD; Zhang SL; Dai B; Zhu YP; Shi GH; Ye DW
Clin Genitourin Cancer; 2013 Jun; 11(2):134-40. PubMed ID: 23058498
[TBL] [Abstract][Full Text] [Related]
2. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
3. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Procopio G; Derosa L; Gernone A; Morelli F; Sava T; Zustovich F; De Giorgi U; Ferrari V; Sabbatini R; Gasparro D; Felici A; Burattini L; Calvani N; Lo Re G; Banna G; Pia Brizzi M; Rizzo M; Ciuffreda L; Iacovelli R; Ferraù F; Taibi E; Bracarda S; Porta C; Galligioni E; Contu A
Future Oncol; 2014 Aug; 10(10):1741-50. PubMed ID: 24641206
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
[TBL] [Abstract][Full Text] [Related]
6. Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Araki H; Tsuzuki T; Kimura T; Tanaka K; Yamada S; Sassa N; Yoshino Y; Hattori R; Gotoh M
Am J Clin Pathol; 2015 Apr; 143(4):492-9. PubMed ID: 25780000
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
8. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
Tafreshi A; Thientosapol E; Liew MS; Guo Y; Quaggiotto M; Boyer M; Davis ID
Asia Pac J Clin Oncol; 2014 Mar; 10(1):60-5. PubMed ID: 24152417
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in renal cell carcinoma.
Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
[TBL] [Abstract][Full Text] [Related]
11. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
12. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
[TBL] [Abstract][Full Text] [Related]
13. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
[TBL] [Abstract][Full Text] [Related]
14. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
Iacovelli R; Verzoni E; Grassi P; Farcomeni A; de Braud F; Procopio G
Tumori; 2014; 100(6):e282-5. PubMed ID: 25688511
[TBL] [Abstract][Full Text] [Related]
15. Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib.
Fujita T; Nishi M; Tabata K; Matsumoto K; Yoshida K; Iwamura M
Anticancer Drugs; 2016 Nov; 27(10):1028-32. PubMed ID: 27537400
[TBL] [Abstract][Full Text] [Related]
16. Survival trends among patients with advanced renal cell carcinoma in the United States.
Shah BK; Ghimire KB
Urol Int; 2015; 94(2):133-6. PubMed ID: 25138899
[TBL] [Abstract][Full Text] [Related]
17. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
18. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
[TBL] [Abstract][Full Text] [Related]
19. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
Gu W; Wang B; Gan H; Zhu Y; Wang H; Shi G; Zhou L; Zhang H; Ye D
Future Oncol; 2016 Aug; 12(15):1783-93. PubMed ID: 27174049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
